Type 2 diabetes mellitus is a progressive and chronic disease manifested by β-cell dysfunction and improved insulin resistance. Higher levels of urokinase-type plasminogen activator receptors have been found to predict morbidity and mortality among diabetic patients with cardiac disease.
This study aims to explore the role of serum urokinase-type plasminogen activator receptor levels as a prognostic marker among type 2 diabetic Iraqi patients.
A total of 70 type 2 diabetic patients (40 male and 30 female) (mean age: 46.20 ± 7.56 years) participated in this study; 35 patients were with cardiovascular disease and 35 were without cardiovascular disease; their ages range were 40–55 years. They were collected from Baghdad Teaching Hospital/Medical City, Baghdad, Iraq through the period from October 2022 to February 2023. Moreover, 30 individuals who were apparent healthy were selected as control group.
There was significant increase in blood glucose, lipid levels with their ratios, and C-reactive protein in diabetic patients as compared to the control. Also, the present results reveal high levels of urokinase-type plasminogen activator receptor (2500.72 ± 12.36 vs. 2255.32 ± 10.15) ρg/mL with OR = 1.80, 95% CI: 1.2, and
It demonstrated that urokinase-type plasminogen activator receptor levels reliably predict morbidity among type 2 diabetic patients presenting with symptoms suggestive of cardiovascular disease.